title: [Glioblastoma treatment in 2010].
abstract: The treatment of glioblastomas requires a multidisciplinary approach because despite the progresses in surgical and iconographic managements associated with research knowledge this disease presently remains incurable and progresses during the 6 months after its diagnose. Current recommendations are that patients with glioblastoma should undergo maximum surgical resection followed by concurrent radiation and chemotherapy with the alkylating drug temozolomide, followed subsequently by additional adjuvant temozolomide for a period of up to 6 months. Temozolomide mechanism of action is complex and we have recently evidenced a temozolomide-associated anti-angiogenic activity in vitro and in vivo on preclinical human glioblastoma models. We describe in the current review the temozolomide-associated antiangiogenic activity. We also describe here the major signaling pathways that can be constitutively activated in migrating glioma cells, and which render these cells resistant to proapoptotic insults such as conventional chemotherapies. In light of this resistance, we therefore describe the targeted therapies and local drug delivery systems which could be used to complement conventional treatments. We have reviewed more than 400 ongoing clinical trials with respect to these new targeted therapy approaches alone or in combination for glioblastoma therapy and we also emphasize the importance of vaccinotherapy. We conclude our review with a therapeutic model that could be used in the light of the present knowledge.
authors.affiliation: Service de Neurochirurgie, Hôpital Erasme, Bruxelles.
authors.forename: R
authors.initials: R
authors.lastname: Djedid
authors.forename: O
authors.initials: O
authors.lastname: Tomasi
authors.forename: A
authors.initials: A
authors.lastname: Haidara
authors.forename: M
authors.initials: M
authors.lastname: Rynkowski
authors.forename: F
authors.initials: F
authors.lastname: Lefranc
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D009389:Neovascularization, Pathologic; D009423:Nervous System Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011493:Protein Kinase C / Q000378:metabolism; D018631:ras Proteins / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D011493:Protein Kinase C; D018631:ras Proteins